Articles tagged with Drug Studies
A new study has shown that SGLT-2 inhibitors, a type of diabetes medication, can decrease cardiovascular risk in adults with chronic kidney disease. The meta-analysis included results from 13 major clinical trials and found a 28% lower risk of worsening kidney disease and death from cardiovascular disease.
A clinical trial found that early use of ECMO devices did not improve outcomes for adults with rapidly deteriorating or severe cardiogenic shock. Participants who received immediate ECMO therapy showed similar clinical outcomes as those receiving early conservative therapy, including treatment with inotropes and vasopressors.
A randomized study compared the effects of torsemide and furosemide in people with heart failure. The study found that both loop diuretics were effective in reducing death and hospitalization rates, with no significant clinical difference between the two medications.
A new study has shown that bivalirudin is a safer and more effective anticoagulant than heparin for treating heart attack patients. The trial found that bivalirudin significantly reduced death, major bleeding, and thrombosis in patients undergoing percutaneous coronary intervention.
A major randomized trial of pemafibrate found no reduction in rates of heart attack, stroke, or cardiovascular death over a five-year period, despite lowering triglycerides by 26 percent. Pemafibrate was effective at reducing remnant cholesterol levels but failed to demonstrate clinical benefits.
A new study published in Alzheimer's & Dementia found that telmisartan, a blood pressure medication, is associated with lower risk of Alzheimer's specifically in Black patients over 60. The study analyzed data from over 5 million patients and suggests that future clinical trials should prioritize minority populations to find or reinfor...
Researchers have found therapies that can help patients with relapsed multiple myeloma who tried CAR-T therapy, including bispecific antibodies and other types of CAR-T cell therapy. The study analyzed 79 patients and found that stem cell transplants and other drug combinations showed some efficacy in these patients.
Researchers at the University of Missouri have successfully used click chemistry to deliver radiopharmaceuticals specifically to tumors in large dogs with bone cancer, increasing effectiveness and minimizing circulation. This breakthrough could pave the way for click chemistry-based treatments for humans with cancer in the future.
A recent study found worsening disparities in cancer drug trial participant diversity from 2000 to 2018, highlighting systemic biases and unequal access to new treatments. The findings underscore the need for increased diversity in phase 1 clinical trials to ensure equitable access to life-saving treatments.
A multicentre clinical trial found that a single dose of COMP360 psilocybin significantly reduced depression symptoms in participants with treatment-resistant depression. The study, involving 233 participants, showed improved outcomes for those receiving the 25mg dose compared to the control group.
A new study published in the New England Journal of Medicine found that semaglutide, an approved obesity drug for adults, also helps adolescents with obesity lose weight and have healthier hearts. After 68 weeks, 72.5% of participants who received semaglutide had achieved at least 5% weight loss compared to just 17% on placebo.
A small clinical trial showed 40% of patients experienced progression-free survival when treated with a CD105 inhibitor, which prevented cancer cells from making splice variant proteins. This approach may resensitize select patients to androgen suppression therapy.
Researchers at the University of Cincinnati are awarded a $3.5 million NIH grant to examine how alcohol use alone or in combination with fentanyl affects HIV medications, including PrEP medication. The study aims to determine metabolite signatures and pharmacological biomarkers of PrEP in HIV-negative populations.
A new study found that only 12% of middle-aged adults are willing to participate in dementia prevention drug trials, citing concerns over the risks involved. The study suggests prioritizing those with a family history or perceived personal risk for dementia and communicating about trial safety could increase participation.
The Alpha Stem Cell Clinic will develop preclinical studies into early and later phase clinical trials with the goal of establishing advanced regenerative medicine treatments. The clinic will also foster greater collaboration with eight similar clinics across the state and educate the public about stem cell and related therapies.
Dr. Volpp's research on behavioral economics and health incentives has significantly advanced understanding of cardiovascular outcomes, leading to changes in benefit design and program offerings. He is also the founder of Penn Center for Health Incentives and Behavioral Economics.
A comparison of two cancer drugs reveals that life cycle management strategy is crucial for a drug's commercial success. The research found that product sales are closely linked to the number of approved indications and inter-organizational alliances.
A new daily anti-clotting pill, edoxaban, shows promise in preventing bleeding and clotting instances rare in children with heart conditions. The study's findings indicate edoxaban is a viable alternative to current treatments, eliminating injections and reducing frequent blood tests.
Researchers at Weill Cornell Medicine have developed a new computational method to map the architecture of human tissues in unprecedented detail. This approach enables powerful new diagnostic strategies for a wide range of diseases, including cancer and chronic conditions.
A large-scale comparison of direct oral anticoagulants has identified apixaban as the drug with the lowest risk of bleeding. The study, published in Annals of Internal Medicine, found that apixaban had a 19-28% lower risk of gastrointestinal bleeding compared to other DOACs.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
The TRIDENT-1 trial suggests that repotrectinib could be effective for treating ROS1 positive non-small cell lung cancer (NSCLC) in patients who have received other targeted treatments and those who have not. The drug showed promising results, with an objective response rate of 79% in patients not previously treated with a ROS TKI.
Researchers have successfully isolated parathyroid stem cells and maintained them in lab as organoids for an extended period. These patient-derived parathyroid organoids (PTOs) closely mimic human parathyroid tissue, enabling the study of parathyroid diseases and drug development.
A new experimental drug has shown promising results in treating liver cancer, with two patients experiencing a partial response to the treatment. The drug, NMS-01940153E, targets an enzyme that plays a critical role in cell division and growth, and its side effects are manageable.
A study found that nearly half of Medicaid beneficiaries who completed opioid rehab did not receive follow-up care or medication-assisted treatment within a month. Patients with prior prescriptions for opioid use disorder medications were 24% more likely to get follow-up care and medication.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
In a patient trial, the AKT inhibitor ipatasertib showed signs of effectiveness in treating advanced cancers. 22% of patients experienced tumor shrinkage, while 56% had stable disease. Further research is needed to understand why some patients responded and others did not.
A phase I clinical trial found that Omomyc (OMO-103) has few side effects and can stabilize disease in some patients. The treatment showed stabilization of disease in 8 out of 17 evaluable patients, including one patient with pancreatic cancer who remained on the study for over six months.
Dr. Christine E. Seidman, a renowned physician-scientist, has made groundbreaking discoveries in genetics and cardiomyopathy, leading to new pharmacological treatments. Her work has improved our understanding of disease risks and has led to unique targeted therapies.
The NCI-MATCH precision medicine cancer trial found a promising signal for the AKT inhibitor ipatasertib, meeting its primary endpoint with a 22% response rate in patients with rare AKT1 E17K tumor gene mutations. The study demonstrated clinically significant activity in patients, warranting additional studies.
RedHill Biopharma's Talicia demonstrates high potential for H. pylori eradication while minimizing systemic antibiotic exposure, outperforming generic rifabutin regimens. Movantik data shows improved patient quality of life and symptom improvement in opioid-induced constipation.
A new drug combination of cefepime and enmetazobactam has been found to be more effective in treating complicated urinary tract infections and acute pyelonephritis than a standard treatment. The study showed that the new combination was successful in treating 79% of patients, compared to 58.9% for the conventional treatment.
Studies on 18beta-glycyrrhetinic acid, human islet amyloid polypeptide (hIAPP), and fluoroquinolone derivatives explore new approaches to treating challenging diseases. Researchers aim to develop better therapeutics for liver diseases, which cause almost 2 million deaths worldwide every year.
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
A new study by Université Laval researchers has identified a link between insulin receptors in brain microvessels and Alzheimer's disease. The findings suggest that drugs targeting these receptors could be effective in treating the condition, expanding the range of potential treatments.
A recent study by Weill Cornell Medicine investigators found that corrupted endothelial cells can protect leukemia cells from chemotherapy drugs. The discovery has the potential to improve drug discovery programs and clinical trials for T-cell acute lymphoblastic leukemia (T-ALL) patients.
The study will gather data from over 500 adults with monkeypox to determine the effectiveness and safety of tecovirimat. Participants with severe disease or high risk of severe disease will receive open-label tecovirimat, while others will be randomly assigned to receive either tecovirimat or placebo.
A meta-analysis of six studies concludes that electroconvulsive therapy (ECT) is more effective than ketamine in quickly relieving major depression symptoms. The analysis, published in JAMA Psychiatry, found no significant differences in ECT's success rate across various age groups and geographic locations.
Scientists at the University of Florida have identified two small molecules that inhibit precancerous cell progression and reverse a key process involved in pancreatic cancer progression. This discovery could lead to earlier treatments and improved survival rates for patients with pancreatic cancer.
Scientists are conducting a first-of-its-kind study to investigate the origin of psychedelic compounds in fungi, including psilocybin found in 'magic mushrooms'. The research aims to understand the evolution of these compounds and their potential applications in medicine and conservation.
A study found that 16.5% of American adults with diabetes ration their insulin, with younger adults and the uninsured being most affected. Insulin rationing is often linked to cost concerns, with many patients delaying purchases or taking less insulin than needed.
Research reveals that pregnant smokers decrease their daily cigarette count by an average of one cigarette per day before realizing they are pregnant. This trend continues in the month following pregnancy recognition, with a decline from nine to five cigarettes per day on average.
A pilot study will investigate the use of medicinal cannabis to ease symptoms in children and adolescents with non-oncological conditions. The trial aims to determine acceptability and feasibility, with potential breakthroughs for treating debilitating symptoms such as pain and seizures.
A clinical trial begins in the Democratic Republic of Congo to evaluate tecovirimat's safety and effectiveness in treating monkeypox. The trial will enroll up to 450 participants, comparing those who receive tecovirimat to placebo, and gather data on disease severity, mortality, and recovery.
A long-term study found that older patients with type 2 diabetes treated with glitazones had a 22% lower risk of developing dementia. These drugs may effectively prevent dementia in high-risk patients and are now worth prioritizing for future clinical studies.
A large clinical trial found that insulin glargine and liraglutide were superior to other diabetes drugs in controlling blood sugars. The study, published in the New England Journal of Medicine, compared four common medications used to treat type 2 diabetes when added to metformin.
Researchers at NYU Grossman School of Medicine have discovered a new treatment approach that suppresses allergic asthma without compromising the body's defenses against flu viruses. The treatment, which targets calcium channels in immune cells, has shown promise in reducing asthmatic inflammation and mucus build-up in mice.
Researchers at CNIC have identified metoprolol as a neuroprotective agent after a stroke, greatly reducing cerebral inflammation and neuronal death. The study's findings suggest that metoprolol may also offer benefits in treating severe Covid-19.
A Phase I/II study found tofacitinib effective in improving skin and organ issues in systemic sclerosis patients. The drug was well-tolerated, with minimal impact on T-cells, suggesting potential repurposing for treatment.
A large randomized clinical trial demonstrated Octagam 10% as an efficacious and well-tolerated treatment option for adult dermatomyositis patients. The study showed improved outcomes in patients with this rare disease, providing a much-needed treatment alternative.
Researchers at the University of Pittsburgh discovered that a cellular channel outside the kidneys plays a crucial role in maintaining healthy blood pressure levels. The study found that subtle mutations in this channel can influence blood pressure, providing a potential new target for existing medications.
A clinical trial of email alerts from pharmacists to doctors and other practitioners found no reduction in risky opioid prescribing, highlighting the need for rigorous testing of policies aimed at making opioid prescribing safer. The study tested behavioral science techniques to encourage safer prescribing practices.
A Johns Hopkins Medicine study found that COVID-19 booster shots are essential for maintaining long-term immunity against infection, particularly among older adults. The results support the CDC vaccination guidelines recommending COVID-19 boosters and highlight the importance of continued research on factors affecting immunity.
A team of researchers identified a protein kinase substrate downstream of the dopamine signaling pathway regulating brain reward behavior. The study found that phosphorylation of potassium voltage-gated channel subfamily Q member 2 (KCNQ2) decreases its channel activity, increasing neuronal excitability and promoting reward behavior.
Scientists have designed compounds that activate the 5HT2a receptor, producing antidepressant and antianxiety effects in mice. The compounds' mechanism of action differs from psychedelics like LSD, offering a potential new approach to developing effective antidepressants with fewer side effects.
Researchers from Xi'an Jiaotong-Liverpool University found that brain stimulation combined with a nose spray containing nanoparticles can improve recovery after ischemic stroke. The treatment increased cognitive and motor functions, and weighed more quickly than those treated with TMS alone.
A recent study found that over 11,000 people treated in US emergency departments for drug-related bike injuries were men, with methamphetamine being the most common substance involved. The study highlights the need for further research and interventions to prevent these incidents.
Researchers at National Jewish Health found pirfenidone effective in slowing ILD progression in RA patients, potentially increasing overall survival. The study was the first prospective treatment trial for this condition.
Research institutes from Finland, Germany, Norway, Spain, and Sweden have launched the Federated European Genome-phenome Archive (Federated EGA) to improve data sharing across national borders. The new platform enables secure access to sensitive human data for research while respecting national data protection regulations.
Lenabasum has been shown to improve skin symptoms in patients with amyopathic dermatomyositis, demonstrating significant reductions in inflammation and disease severity. The study's findings suggest that lenabasum is a well-tolerated treatment option for refractory skin disease.